Recombinant VAR2CSA malaria protein-targeted exosome-mediated DACT2 gene therapy for effective glioma treatment
Source abstract
Abstract
A good non-viral vector is the key to the success of gene delivery and therapy; hence, modified exosomes may overcome the physiological barrier in the delivery in vivo. This study aims to design a novel non-viral vector and verify its gene delivery function in vitro and in vivo for dapper homolog 2 (DACT2) genes. In this study, amphipathicity cationic exosomes with receptor targeted function and DACT2 gene loading function were constructed by exosomes, PEG, glycidyl hexadecyl dimethylammonium chloride, and recombinant VAR2CSA malaria protein (RVP) antibody. Characterizations of RVP antibody and PEG modified cationic lipid exosome (RVP-CL) nanocomplexes were evaluated by dynamic light scattering, atomic force microscopy, FTIR, and so on. The DNA condensation ability and stability were assessed by agarose gel electrophoresis. Cellular uptake efficiency and cytotoxicity in glioma cells were investigated. Furthermore, the tumor suppressive effect was evaluated in vitro and in vivo. The results indicated that RVP-CL had a uniform size of 100–200 nm and positive zeta potential. With high uptake efficiency, RVP-CL can rapidly target, recognize, and enter the glioma cell (KNS-42 and U118 mg) and release the gene. Moreover, RVP-CL/DACT2 can effectively inhibit the growth of glioma cells in vitro and in vivo. The modified cationic exosomes may offer a promising strategy for gene delivery in the treatment of RVP-positive gliomas or other tumors.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Extracellular vesicles in disease · Mosquito-borne diseases and control
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Neurosurgery Department, Hangzhou Children’s Hospital , Hangzhou 310000, China
Funding
Zhejiang Medical Health Science and Technology Project · Zhejiang Province Traditional Chinese Medicine Science and Technology Project
References (39)
Show source-provided references
1. Upregulation of DACT2 suppresses proliferation and enhances apoptosis of glioma cell via inactivation of YAP signaling pathway10.1038/cddis.2017.385 ↗
2. Glioma targeted therapy: Insight into future of molecular approaches10.1186/s12943-022-01513-z ↗
3. Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition10.1016/j.ccell.2022.04.009 ↗
4. Glioma-associated microglia/macrophages (GAMs) in glioblastoma: Immune function in the tumor microenvironment and implications for immunotherapy10.3389/fimmu.2023.1123853 ↗
5. EANO–EURACAN–SNO guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors10.1093/neuonc/noac188 ↗
6. Transcription factors with targeting potential in gliomas10.3390/ijms23073720 ↗
7. Therapeutic activity of retroviral replicating vector-mediated prodrug activator gene therapy for pancreatic cancer10.1038/s41417-018-0020-7 ↗
8. Mechanism of dact2 gene inhibiting the occurrence and development of liver fibrosis10.14715/cmb/2021.67.6.5 ↗
9. Association between promoter hypermethylation of the DACT2 gene and tumor stages in breast cancer
10. DACT2 is a candidate tumor suppressor and prognostic marker in esophageal squamous cell carcinoma10.1158/1940-6207.capr-12-0352 ↗
11. A possible role of transient AChE expression in the medial geniculate of developing rats10.1097/00001756-199604100-00023 ↗
12. Pilomyxoid astrocytoma (PMA) shows significant differences in gene expression vs pilocytic astrocytoma (PA) and variable tendency toward maturation to PA10.1111/bpa.12239 ↗
13. The new 6q27 tumor suppressor DACT2, frequently silenced by CpG methylation, sensitizes nasopharyngeal cancer cells to paclitaxel and 5-FU toxicity via β-catenin/Cdc25c signaling and G2/M arrest10.1186/s13148-018-0459-2 ↗
14. Synthetic adeno-associated viral vector efficiently targets mouse and nonhuman primate retina in vivo10.1089/hum.2017.154 ↗
15. A hepatic pDNA delivery system based on an intracellular environment sensitive vitamin E-scaffold lipid-like material with the aid of an anti-inflammatory drug10.1016/j.jconrel.2018.04.022 ↗
16. DNA associated with circulating exosomes as a biomarker for glioma10.3390/genes11111276 ↗
17. DNA vectors generating engineered exosomes potential CTL vaccine candidates against AIDS, hepatitis B, and tumors10.1007/s12033-018-0114-3 ↗
18. Exploiting exosomes in cancer liquid biopsies and drug delivery10.1002/adhm.201801268 ↗
19. Exosomes: A role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment10.2174/1566523214666141224100612 ↗
20. Analyzing the circulating microRNAs in exosomes/extracellular vesicles from serum or plasma by qRT-PCR10.1007/978-1-62703-453-1_10 ↗
21. The mechanism and efficiency affecting factor cationic liposome transfection
22. Development of a novel cationic liposome: Evaluation of liposome mediated transfection and anti-proliferative effects of miR-101 in acute myeloid leukemia10.1016/j.jddst.2018.02.005 ↗
23. Capture and detection of circulating glioma cells using the recombinant VAR2CSA malaria protein10.3390/cells8090998 ↗
24. Properties and evaluation of quaternized chitosan/lipid cation polymeric liposomes for cancer-targeted gene delivery10.1021/la401166v ↗
25. Development of self-assembling peptide nanovesicle with bilayers for enhanced EGFR-targeted drug and gene delivery10.1016/j.biomaterials.2015.12.015 ↗
26. In utero exposure to a high-fat diet programs hepatic hypermethylation and gene dysregulation and development of metabolic syndrome in male mice10.1210/en.2017-00334 ↗
27. Long non-coding RNA in glioma: Target miRNA and signaling pathways10.7754/clin.lab.2018.180107 ↗
28. Updated insights on EGFR signaling pathways in glioma10.3390/ijms22020587 ↗
29. High-efficiency transduction of liver cancer cells by recombinant adeno-associated virus serotype 3 vectors10.3791/2538-v ↗
30. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis10.1186/s12943-019-0957-7 ↗
31. Loss of Tff1 promotes pro-inflammatory phenotype with increase in the levels of RORγt+ T lymphocytes and Il-17 in mouse gastric neoplasia10.7150/jca.19639 ↗
32. Competition of charge-mediated and specific binding by peptide-tagged cationic liposome–DNA nanoparticles in vitro and in vivo10.1016/j.biomaterials.2018.02.052 ↗
33. Toxicity of cationic lipids and cationic polymers in gene delivery10.1016/j.jconrel.2006.04.014 ↗
34. Functional delivery of lipid-conjugated siRNA by extracellular vesicles10.1016/j.ymthe.2017.03.021 ↗
35. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes10.1038/nbt.1807 ↗
36. Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis10.1016/j.jconrel.2019.12.005 ↗
37. Exosomes-coated bcl-2 siRNA inhibits the growth of digestive system tumors both in vitro and in vivo10.1016/j.ijbiomac.2020.06.052 ↗
38. Engineered targeting tLyp-1 exosomes as gene therapy vectors for efficient delivery of siRNA into lung cancer cells10.1016/j.ajps.2019.04.002 ↗
39. iRGD-modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation10.1002/1878-0261.13052 ↗